

- Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. *Clin Cancer Res* 2006;12:6243s–6249s.
- Goblirsch MJ, Zwolak PP, Clohisey DR. Biology of bone cancer pain. *Clin Cancer Res* 2006;12:6231s–6235s.
- Plunkett T, Smith P, Rubens R. Risk of complications from bone metastases in breast cancer: implications for management. *Eur J Cancer* 2000;36:476–482.
- Siclar VA, Guise TA, Chirgwin JM. Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. *Cancer Metastasis Rev* 2006;25:621–633.
- Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. *J Natl Cancer Inst* 2005;97:59–69.
- Tschirhart CE, Roth SE, Whyne CM. Biomechanical assessment of stability in the metastatic spine following percutaneous vertebroplasty: effects of cement distribution patterns and volume. *J Biomech* 2005;38:1582–1590.
- Green MC, Hortobagyi GN. Systemic treatments: chemotherapy. In Jamin C, Coleman RE, Coia LR, et al., eds. *Textbook of bone metastases*. Chichester, England: Wiley; 2005:261.
- Roelofs AJ, Thompson K, Gordon S, et al. Molecular mechanisms of action of bisphosphonates: current status. *Clin Cancer Res* 2006;12:6222s–6230s.
- Coleman RE, McCloskey EV. Bisphosphonates in oncology. *Bone* 2011;49:71–76.
- Pavakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. *Cochrane Database Syst Rev* 2005;3:CD003474.
- Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in treatment of skeletal complications in patients with advanced multiple myeloma or breast cancer: a randomized, double-blind, multicenter, comparative trial. *Cancer* 2003;98:1735–1744.
- Body JJ, Diel IJ, Lichinitser MR, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. *Ann Oncol* 2003;14:1399–1405.
- Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. *N Engl J Med* 1996;334:488–493.
- Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomized controlled trial. *Lancet* 2010;376:1989–1999.
- Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with advanced prostate cancer and bone metastasis. *J Natl Cancer Inst* 2004;96:879–882.
- Rosen LS, Gordon D, Tchekmedyan S, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. *Cancer* 2004;100:2613–2621.
- Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappa B ligand inhibitor, Denosumab, in patients with multiple myeloma or bone metastases from breast cancer. *Clin Cancer Res* 2006;12:1221–1228.
- Lipton A, Steger GG, Figueroa J, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. *Clin Cancer Res* 2008;14:6690–6696.
- Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. *J Clin Oncol* 2010;28:5132–5139.
- Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study. *Lancet* 2011;377:813–822.
- Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. *J Clin Oncol* 2011;29:1125–1132.
- Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. *Ann Oncol* 2012;23:1341–1347.
- Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. *Ann Oncol* 2008;19:420–432.
- Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. *J Clin Oncol* 2011;29:1221–1227.
- Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. *Eur Urol* 2011;59:572–583.
- Terpos E, Morgan G, Dimopoulos MA, et al. International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease. *J Clin Oncol* 2013;31:2347–2357.
- Coleman R, Costa L, Saad F, et al. Consensus on the utility of bone markers in the malignant bone disease setting. *Crit Rev Oncol Hematol* 2011;80:411–432.
- Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. *N Engl J Med* 2013;369:213–223.
- Tong D, Gillick L, Hendrickson F. The palliation of symptomatic osseous metastases: final results of the study by the Radiation Therapy Oncology Group. *Cancer* 1982;50:893–899.
- Blitzer P. Reanalysis of the RTOG study of the palliation of symptomatic osseous metastases. *Cancer* 1985;55:1468–1472.
- Chow E, Hoskin P, Mitera G, et al. Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. *Int J Radiat Oncol Biol Phys* 2012;82:1730–1737.
- Bone Pain Trial Working Party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomized comparison with multi-fraction schedule over 12 months of patient follow-up. *Radiother Oncol* 1999;52:111–121.
- Steenland E, Leer J, van Houwelingen H, et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. *Radiother Oncol* 1999;52:101–109.
- Van den Hout WB, van der Linden YM, Steenland E, et al. Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. *J Natl Cancer Inst* 2003;95:222–229.
- Ratanatharathorn V, Powers W, Moss W, et al. Bone metastasis: review and critical analysis of random allocation trials of local field treatment. *Int J Radiat Oncol Biol Phys* 1999;44:1–18.
- Wu JS, Wong R, Johnston M, et al. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. *Int J Radiat Oncol Biol Phys* 2003;55:594–605.
- Sze WM, Shelley M, Held I, et al. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy—a systemic review of randomised trials. *Clin Oncol* 2003;15:345–352.
- Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. *J Natl Cancer Inst* 2005;97:798–804.
- Kaasa S, Brenne E, Lund J, et al. Prospective randomized multicentre trial on single fraction radiotherapy (8 Gy X 1) versus multiple fractions (3 Gy X 10) in the treatment of painful bone metastases: phase III randomized trial. *Radiother Oncol* 2006;79:278–284.
- Chow E, Zeng L, Salvo N, et al. Update on the systematic review on palliative radiotherapy trials for bone metastases. *Clin Oncol* 2012;24:112–124.
- Roos DE, Turner SL, O'Brien PC, et al. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). *Radiother Oncol* 2005;75:54–63.
- Hoskin PJ, Price P, Easton D, et al. A prospective randomized trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. *Radiother Oncol* 1992;23:74–78.
- Jeremic B, Shibamoto Y, Acimovic L, et al. A randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain. *Int J Radiat Oncol Biol Phys* 1998;41:161–167.
- Fitzpatrick PJ, Rider WD. Half body radiotherapy. *Int J Radiat Oncol Biol Phys* 1976;1:197–207.
- Hoskin PJ, Ford HT, Harmer CL. Hemibody irradiation (HBI) for metastatic bone pain in two histologically distinct groups of patients. *Clin Oncol (R Coll Radiol)* 1989;1:67–69.
- Van Dyk J, Keane TJ, Kan S, et al. Radiation pneumonitis following large single dose irradiation: a re-evaluation based on absolute dose to lung. *Int J Radiat Oncol Biol Phys* 1981;7:461–467.
- Zelevsky MJ, Scher HI, Forman JD, et al. Palliative hemiskeletal irradiation for widespread metastatic prostate cancer: a comparison of single dose and fractionated regimens. *Int J Radiat Oncol Biol Phys* 1989;7:1281–1285.
- Poulter CA, Cosmatos D, Rubin P, et al. A report of RTOG 8206: a phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases. *Int J Radiat Oncol Biol Phys* 1992;23:207–214.
- Salazar OM, Sandhu T, da Motta NW, et al. Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized Phase III trial of the International Atomic Energy Agency (IAEA). *Int J Radiat Oncol Biol Phys* 2001;50:765–775.
- Mithal NP, Needham PR, Hoskin PJ. Retreatment with radiotherapy for painful bone metastases. *Int J Radiat Oncol Biol Phys* 1994;29:1011–1014.
- Jeremic B, Shibamoto Y, Igrutinovic I. Single 4 Gy re-irradiation for painful bone metastases following single fraction radiotherapy. *Radiother Oncol* 1999;52:123–127.
- Jeremic B, Shibamoto Y, Igrutinovic I. Second single 4 Gy re-irradiation for painful bone metastasis. *J Pain Symptom Manage* 2002;23:26–30.
- van der Linden YM, Lok JJ, Steenland E, et al. Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment. Dutch Bone Metastases Study Group. *Int J Radiat Oncol Biol Phys* 2004;59:528–537.
- Chow E, van der Linden Y, Roos D, et al. A randomized trial of single versus multiple fractions for re-irradiation of painful bone metastases: NCIC CTG SC.20. *J Clin Oncol* 2013;31:Abstr 9502.
- Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam

- irradiation in the management of endocrine resistant metastatic prostate cancer. *Int J Radiat Oncol Biol Phys* 1993;25:805–813.
56. McEwan AJ, Amoyte CA, McCowan DG, et al. A retrospective analysis of the cost effectiveness of treatment with Metastron (89Sr-chloride) in patients with prostate cancer metastatic to bone. *Nucl Med Commun* 1994;15:499–504.
  57. Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. *Radiother Oncol* 1994;31:33–40.
  58. Hird A, Chow E, Zhang L, et al. Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: results from three Canadian cancer centers. *Int J Radiat Oncol Biol Phys* 2009;75:193–197.
  59. Van der Linden Y, Kroon H, Dijkstra S, et al. Simple radiographic parameter predicts fracturing in metastatic femoral bone lesions: results from a randomized trial. *Radiother Oncol* 2003;69:21–31.
  60. Townsend PW, Smalley SR, Cozad SC, et al. Role of postoperative radiation therapy after stabilization of fractures caused by metastatic disease. *Int J Radiat Oncol Biol Phys* 1995;31:43–49.
  61. Sahgal A, Roberge D, Schellenberg D, et al. The Canadian Association of Radiation Oncology scope of practice guidelines for lung, liver and spine stereotactic body radiotherapy. *Clin Oncol (R Coll Radiol)* 2012;24:629–639.
  62. Sahgal A, Bilsky M, Chang EL, et al. Stereotactic body radiotherapy for spinal metastases: current status, with a focus on its application in the postoperative patient. *J Neurosurg Spine* 2011;14:151–166.
  63. Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. *Int J Radiat Oncol Biol Phys* 2011;79:965–976.
  64. Wang XS, Rhines LD, Shiu AS, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. *Lancet Oncol* 2012;13:395–402.
  65. Cox BW, Spratt DE, Lovelock M, et al. International Spine Radiosurgery Consortium Consensus Guidelines for target volume definition in spinal stereotactic radiosurgery. *Int J Radiat Oncol Biol Phys* 2012;83:e597–e605.
  66. Patel VB, Wegner RE, Heron DE, et al. Comparison of whole versus partial vertebral body stereotactic body radiation therapy for spinal metastases. *Technol Cancer Res Treat* 2012;11:105–115.
  67. Chiang A, Zeng L, Zhang L, et al. Pain flare is a common adverse event in steroid-naïve patients after spine stereotactic body radiation therapy: a prospective clinical trial. *Int J Radiat Oncol Biol Phys* 2013;86:638–642.
  68. Sahgal A, Ma L, Weinberg V, et al. Re-irradiation human spinal cord tolerance for stereotactic body radiotherapy. *Int J Radiat Oncol Biol Phys* 2012;82:107–116.
  69. Sahgal A, Weinberg V, Ma L, et al. Probabilities of radiation myelopathy specific to stereotactic body radiation therapy to guide safe practice. *Int J Radiat Oncol Biol Phys* 2013;85:341–347.
  70. Sahgal A, Atenafu EG, Chao S, et al. Vertebral compression fracture after spine stereotactic body radiotherapy: a multi-institutional analysis with a focus on radiation dose and the spinal instability neoplastic score. *J Clin Oncol* 2013;31:3426–3431.
  71. Al-Omair A, Smith R, Kiehl TR, et al. Radiation-induced vertebral compression fracture following spine stereotactic radiosurgery: clinicopathological correlation. *J Neurosurg Spine* 2013;18:430–435.
  72. Sahgal A, Whyne CM, Ma L, et al. Vertebral compression fracture after stereotactic body radiotherapy for spinal metastases. *Lancet Oncol* 2013;14:e310–e320.
  73. Cunha MV, Al-Omair A, Atenafu EG, et al. Vertebral compression fracture (VCF) after spine stereotactic body radiation therapy (SBRT): analysis of predictive factors. *Int J Radiat Oncol Biol Phys* 2012;84:e343–e349.
  74. Damron TA, Sim FH. Surgical treatment for metastatic disease of the pelvis and the proximal end of the femur. *J Bone J Surg* 2000;82:113–126.
  75. Pugh J, Sherry HS, Futterman B, et al. Biomechanics of pathologic fractures. *Clin Orthop* 1982;169:109–114.
  76. Mirel H. Metastatic disease in long bones: a proposed scoring system for diagnosing impending pathologic fractures. *Clin Orthop Relat Res* 1989;249:256–264.
  77. Beals RK, Lawton GD, Snell WH. Prophylactic internal fixation of the femur with metastatic breast cancer. *Cancer* 1971;28:1350–1354.
  78. Fidler M. Incidence of fracture through metastases in long bones. *Acta Orthop Scand* 1987;52:623–627.
  79. Keene JS, Sellinger DS, McBeath AA, et al. Metastatic breast cancer in the femur. A search for the lesion at risk of fracture. *Clin Orthop* 1986;203:282–288.
  80. Ward WG, Hosengeck S, Dorey FJ, et al. Metastatic disease of the femur: surgical treatment. *Clin Orthop* 2003;415:230–244.
  81. Chow E, Holden L, Rubenstein J, et al. Computed tomography (CT) evaluation of breast cancer patients with osteolytic bone metastases undergoing palliative radiotherapy: a feasibility study. *Radiother Oncol* 2004;70:291–294.
  82. Zickel RE, Mouradian WH. Intramedullary fixation of pathological fractures and lesions of the subtrochanteric region of the femur. *J Bone Joint Surg* 1976;58:1061–1066.
  83. Heinrich H, Kremer P, Winter H, et al. Transesophageal 2 dimensional echocardiography in hip endoprostheses. *Anaesthetist* 1985;34:118–123.
  84. Sturmer KM. Measurement of intramedullary pressure in an animal experiment and propositions to reduce the pressure increase. *Injury* 1993;24:S7–S21.
  85. Crowninshield RD, Johnston FC, Andres JG, et al. A biomechanical investigation of the human hip. *J Biomech* 1978;11:75–85.
  86. Patriarco AC, Mann RW, Simon SR, et al. An evaluation of the approaches of optimization models in the prediction of muscle forces during human gait. *J Biomech* 1981;14:513–525.
  87. Jung ST, Ghert MA, Harrelson JM, et al. Treatment of osseous metastases in patients with renal cell carcinoma. *Clin Orthop* 2003;409:223–231.
  88. Roscoe MW, McBroom FJ, St Louis E, et al. Preoperative embolization in the treatment of osseous metastases from renal cell carcinoma. *Clin Orthop* 1989;238:302–307.
  89. Breslau J, Eskridge JM. Preoperative embolization of spinal tumors. *J Vasc Interv Radiol* 1995;6:871–875.
  90. Manke C, Bretschneider T, Lenhart M, et al. Spinal metastases from renal cell carcinoma: effect of preoperative particle embolization on intraoperative blood loss. *Am J Neuroradiol* 2001;22:997–1003.
  91. Atesok K, Leibergall M, Sucher E, et al. Treatment of pathological humeral shaft fractures with undreamed humeral nail. *Ann Surg Oncol* 2007;14:1493–1498.
  92. Dijkstra S, Stapert J, Boxma H, et al. Treatment of pathological fractures of the humeral shaft due to bone metastases: a comparison of intramedullary locking nail and plate osteosynthesis with adjunctive bone cement. *Eur J Surg Oncol* 1996;22:621–626.
  93. Wai EK, Finkelstein JA, Tangente RP, et al. Quality of life in surgical treatment of metastatic spine disease. *Spine* 2003;28:508–512.
  94. Tatsui H, Onomura T, Morishita S, et al. Survival rates of patients with metastatic spinal cancer after scintigraphic detection of abnormal radioactive accumulation. *Spine* 1996;21:2143–2148.
  95. Finkelstein JA, Zaveri G, Wai E, et al. A population based study of surgery for spinal metastases. Survival rates and complications. *J Bone Joint Surg* 2003;85:1045–1050.
  96. Argenson C, Cordonnier D, Enkaoua E, et al. Place de la chirurgie dans la traitement des métastases du rachis. SOF.C.O.T. Reunion Annuelle, Novembre 1996. *Rev Chir Orthop* 1997;83:109–174.
  97. Wise JJ, Fischgrund JS, Herkowitz HN, et al. Complications, survival rates, and risk factors of surgery for metastatic disease of the spine. *Spine* 1999;24:1943–1951.
  98. Bridwell KH, Jenny AB, Saul T, et al. Posterior segmental spinal instrumentation (PSSI) with posterolateral decompression and debulking for metastatic thoracic and lumbar disease: limitations of the technique. *Spine* 1998;13:1383–1394.
  99. Ghogawala Z, Mansfield F, Borges L. Spinal radiation before surgical decompression adversely affects outcomes of surgery for symptomatic metastatic spinal cord compression. *Spine* 2001;26:818–824.
  100. Deramond H, Depriester C, Galibert P, et al. Percutaneous vertebroplasty with polymethylmethacrylate: technique indications and results. *Radiol Clin North Am* 1998;36:533–546.
  101. Alvarez L, Perez-Higueras A, Quinones D, et al. Vertebroplasty in the treatment of vertebral tumors: post procedural outcome and quality of life. *Eur Spine J* 2003;12:356–360.
  102. Chiras J, Depriester C, Weill A, et al. Percutaneous vertebral surgery: techniques and indications. *J Neuroradiol* 1997;24:45–59.
  103. Jang JS, Lee SH, Jung SK. Pulmonary embolism of polymethylmethacrylate after percutaneous vertebroplasty: a report of three cases. *Spine* 2002;27:E416–E418.
  104. Mousavi P, Roth S, Finkelstein J, et al. Volumetric quantification of cement leakage following percutaneous vertebroplasty in metastatic and osteoporotic vertebrae. *J Neurosurg* 2003;99:56–59.